Financial Performance Expectations - The company expects a net loss of between 68 million and 100 million yuan for the year 2024, with a significant decrease compared to a net profit of approximately 75.27 million yuan in 2023, representing a change of about -32.86% to -9.66%[1] - The projected operating revenue for 2024 is estimated to be between 180 million and 220 million yuan, down from 235.42 million yuan in 2023[1] - The company anticipates a loss of 63 million to 95 million yuan after deducting non-recurring gains and losses, reflecting a decrease of approximately -27.49% to -15.45% compared to the previous year[1] - Basic earnings per share are expected to be a loss of between 0.0660 yuan and 0.0971 yuan, compared to a loss of 0.0731 yuan per share in 2023[1] Reasons for Performance Decline - The decline in performance is primarily attributed to increased expenses related to securities false statement liability disputes and a decrease in main business revenue due to market competition[3] Asset Impairment and Delisting Risks - The company is currently undergoing asset impairment testing, with the estimated impact being preliminary and subject to final audit results[5] - If the audited profit total, net profit, and net profit after deducting non-recurring gains and losses are all negative, and the operating revenue is below 300 million yuan, the company's stock will face delisting risk warnings[5]
四环生物(000518) - 2024 Q4 - 年度业绩预告